State of the Industry with Pamela Silver
Pamela is a founding member of the Department of Systems Biology at Harvard Medical School. Her work involves building synthetic cells that act as sensors, memory devices, bio-computers, producers of high-value commodities and energy from the sun, and novel subsystems such as proteins with designed properties for therapeutic use. Among her most recent innovations are bacteria that can sense and respond to gut inflammation. She also created the Bionic Leaf, which couples sunlight capture to bioproduction at an efficiency exceeding plants.
- What our response to the novel coronavirus reveals to her about science and technology
- What synthetic biology is doing well, and what work remains to be done
- How Pamela see the future of health, medicine, and industry
We’re not going back to normal – The COVID pivot for science and society
Like the rest of the world, the synthetic biology industry is undergoing a pivot during this unprecedented time. If there’s a silver lining to the pandemic, it’s pushing us all to change how we do things—and that’s for the best, because normal wasn’t good enough. Join host John Cumbers and a panel of distinguished guests as we take a look at how the pandemic reveals who is swimming naked, the things that matter, and how life will never be the same. Topics will range from supply chains and biomanufacturing to climate change and science policies to the changing workforce and building a more equitable, sustainable economy.
- Pamela Silver, Harvard Medical School
- Esther Dyson, Chairman of EDventure Holdings and Executive Founder of Wellville
- Drew Endy, Stanford University
- Steven L. Kwast, Lt Gen (Ret), Chief Global Officer & President of Genesis Systems, LLC
- Karen Watson, Strategic Communications Consultant and former advisor to Michelle Obama
- Nishan Degnarain, Visiting Professor at London School of Economics and Member of WEF’s Global Expert Network